Stock Research: Nektar

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Nektar

NasdaqGS:NKTR US6402681083
6
  • Value
    71
  • Growth
    16
  • Safety
    Safety
    6
  • Combined
    6
  • Sentiment
    42
  • 360° View
    360° View
    6
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for immunological dysfunction in autoimmune and chronic inflammatory diseases and oncology. The company focuses on medicines targeting biological pathways to stimulate the immune response to fight cancer. Nektar Therapeutics operates in the biotechnology industry. In the last fiscal year, the company had $400 million in market cap, profits of $68 million, revenue of $98 million, and 61 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 6 (better than 6% compared with alternatives), overall professional sentiment and financial characteristics for the stock Nektar are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Nektar. The only rank that is above average is the consolidated Safety Rank at 71, which means that the company has a financing structure that is safer than those of 71% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 6, which means that the share price of Nektar is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 16, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 42, which means that professional investors are more pessimistic about the stock than for 58% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
NASDAQ
D.J. US Pharmaceutical
S&P MIDCAP
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
16 73 39 75
Safety
Safety
71 93 94 77
Sentiment
42 16 4 20
360° View
360° View
6 49 60 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
69 17 1 29
Opinions Change
95 50 50 50
Pro Holdings
n/a 70 19 78
Market Pulse
11 15 13 14
Sentiment
42 16 4 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
6 22 77 21
Growth
16 73 39 75
Safety Safety
71 93 94 77
Combined
6 81 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
81 81 81 8
Price vs. Earnings (P/E)
5 49 74 14
Price vs. Book (P/B)
8 28 81 42
Dividend Yield
1 1 1 1
Value
6 22 77 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
4 4 6 97
Profit Growth
17 71 66 25
Capital Growth
4 85 100 85
Stock Returns
100 87 5 43
Growth
16 73 39 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 100 100 100
Refinancing
42 92 100 71
Liquidity
25 25 22 11
Safety Safety
71 93 94 77

Similar Stocks

Discover high‑ranked alternatives to Nektar and broaden your portfolio horizons.

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

CF Industries

NYSE:CF
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.